CR20120359A - Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle) - Google Patents

Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle)

Info

Publication number
CR20120359A
CR20120359A CR20120359A CR20120359A CR20120359A CR 20120359 A CR20120359 A CR 20120359A CR 20120359 A CR20120359 A CR 20120359A CR 20120359 A CR20120359 A CR 20120359A CR 20120359 A CR20120359 A CR 20120359A
Authority
CR
Costa Rica
Prior art keywords
erythemate
sle
treatment
humanized antibodies
system lupus
Prior art date
Application number
CR20120359A
Other languages
English (en)
Inventor
Frank Osterroth
Christoph Uherek
Christoph Bruecher
Peter Roettgen
Benjamin Daelken
Andre Engling
Chantal Zuber
Niklas Czeloth
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0920940A external-priority patent/GB0920940D0/en
Priority claimed from GB0920933A external-priority patent/GB0920933D0/en
Priority claimed from GB0920942A external-priority patent/GB0920942D0/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of CR20120359A publication Critical patent/CR20120359A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporciona un anticuerpo humanizado o quimérico o su frangmento, cpaz de ligar a interleucina-10 (IL-10), en donde el anticuerpo o su fragmento: (i) liga a la misma región de IL-10 que el receptor IL-10a (IL-10Ra) y no es capaz de ligar IL-10 cuando IL-10 se liga al receptor.
CR20120359A 2009-11-30 2012-06-28 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle) CR20120359A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0920940A GB0920940D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920933A GB0920933D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920942A GB0920942D0 (en) 2009-11-30 2009-11-30 Agent for treating disease

Publications (1)

Publication Number Publication Date
CR20120359A true CR20120359A (es) 2013-01-25

Family

ID=43798505

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20120358A CR20120358A (es) 2009-11-30 2012-06-28 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistémico eritematoso (sle)
CR20120359A CR20120359A (es) 2009-11-30 2012-06-28 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20120358A CR20120358A (es) 2009-11-30 2012-06-28 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistémico eritematoso (sle)

Country Status (17)

Country Link
US (4) US8852871B2 (es)
EP (2) EP2470209B1 (es)
JP (2) JP2013511994A (es)
KR (2) KR101802260B1 (es)
CN (2) CN102711829B (es)
AU (2) AU2010323036B2 (es)
BR (2) BR112012012912A2 (es)
CA (2) CA2782004A1 (es)
CO (1) CO6561779A2 (es)
CR (2) CR20120358A (es)
IL (2) IL219955A (es)
MX (2) MX350206B (es)
NZ (2) NZ600894A (es)
RU (2) RU2581812C2 (es)
SG (2) SG10201407936XA (es)
WO (2) WO2011064398A1 (es)
ZA (1) ZA201204843B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064398A1 (en) 2009-11-30 2011-06-03 Biotest Ag Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
RU2679889C2 (ru) 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
US20160068583A1 (en) * 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
WO2015120364A1 (en) * 2014-02-10 2015-08-13 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies
JP2017535783A (ja) * 2014-11-28 2017-11-30 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ センサー表面でアナライト−リガンド結合を測定するための方法
CN107108728A (zh) * 2014-12-15 2017-08-29 莫佛塞斯公司 Il‑17c的抗体
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
EP3341012A4 (en) 2015-08-25 2019-03-20 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
AU2016362777B2 (en) 2015-12-04 2020-01-30 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
WO2019072566A1 (en) 2017-10-10 2019-04-18 Biotest Ag COMBINATION OF ANTI-IL10 AND ANTI-PD1 ANTIBODIES FOR THE TREATMENT OF CANCER
AR114112A1 (es) 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
CN116997359A (zh) 2020-11-18 2023-11-03 阿斯利康(瑞典)有限公司 类固醇节制
IL305969A (en) * 2021-03-23 2023-11-01 Organogenesis Inc Kits and composition methods for characterizing the anti-inflammatory response of a product

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69203443T2 (de) * 1991-01-16 1995-12-07 Schering Corp Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
HU224437B1 (hu) 1991-08-06 2005-09-28 Schering Corp. Eljárás interleukin-10 analógokat vagy antagonistákat tartalmazó endotoxin- vagy szuperantigén-indukált toxicitás kezelésére szolgáló gyógyszerkészítmények előállítására
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
DE19529026C2 (de) 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
RS51318B (sr) 2002-12-16 2010-12-31 Genentech Inc. Varijante imunoglobulina i njihova upotreba
PE20090047A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
WO2009032661A1 (en) * 2007-08-29 2009-03-12 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2011064398A1 (en) * 2009-11-30 2011-06-03 Biotest Ag Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Also Published As

Publication number Publication date
JP6005519B2 (ja) 2016-10-12
EP2470209B1 (en) 2020-01-01
CN102811736A (zh) 2012-12-05
US20120321617A1 (en) 2012-12-20
CA2782007A1 (en) 2011-06-03
NZ600899A (en) 2014-09-26
US9540436B2 (en) 2017-01-10
KR101802261B1 (ko) 2017-11-28
RU2587622C2 (ru) 2016-06-20
RU2012127380A (ru) 2014-01-10
AU2010323036B2 (en) 2015-01-29
US8956607B2 (en) 2015-02-17
CN102811736B (zh) 2016-01-20
CR20120358A (es) 2013-01-23
RU2581812C2 (ru) 2016-04-20
IL219955A (en) 2016-08-31
MX2012006197A (es) 2012-06-19
WO2011064399A1 (en) 2011-06-03
WO2011064398A1 (en) 2011-06-03
MX2012006198A (es) 2012-06-19
IL219954A (en) 2016-10-31
IL219955A0 (en) 2012-07-31
AU2010323037A1 (en) 2012-07-19
KR101802260B1 (ko) 2017-11-28
BR112012012912A2 (pt) 2016-10-25
AU2010323036A1 (en) 2012-07-19
RU2012127381A (ru) 2014-01-10
NZ600894A (en) 2014-09-26
KR20120115289A (ko) 2012-10-17
ZA201204843B (en) 2020-02-26
JP2013511994A (ja) 2013-04-11
US20150218270A1 (en) 2015-08-06
MX343228B (es) 2016-10-26
EP2470208A1 (en) 2012-07-04
US20150064179A1 (en) 2015-03-05
CN102711829A (zh) 2012-10-03
SG10201407936XA (en) 2015-01-29
CO6561779A2 (es) 2012-11-15
EP2470209A1 (en) 2012-07-04
AU2010323037B2 (en) 2015-01-29
IL219954A0 (en) 2012-07-31
CA2782007C (en) 2018-07-24
CA2782004A1 (en) 2011-06-03
SG10201407935YA (en) 2015-01-29
BR112012012917A2 (pt) 2016-10-25
JP2013511995A (ja) 2013-04-11
US9605066B2 (en) 2017-03-28
US20120321618A1 (en) 2012-12-20
KR20120103664A (ko) 2012-09-19
MX350206B (es) 2017-08-28
US8852871B2 (en) 2014-10-07
CN102711829B (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
CR20120359A (es) Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle)
NZ607969A (en) Cd33 binding agents
NZ598713A (en) Insulin receptor binding antibodies
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
EP3786183A3 (en) Antigen binding constructs to cd3
TN2013000417A1 (en) Antibody polypeptides that antagonize cd40
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
SG10201703798YA (en) Antibodies with modified affinity to fcrn that promote antigen clearance
EA201490454A1 (ru) Тернесит в качестве активатора для латентно-гидравлических и пуццолановых веществ
MY188469A (en) Low affinity blood brain barrier receptor antibodies and uses therefor
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
WO2009026117A3 (en) Novel compounds
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
MX343659B (es) Proteínas de unión receptoras fc.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
ECSP13012649A (es) Anticuerpos ANTI-IL-23
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
EA201300978A1 (ru) Антитела к сеа
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2015003150A (es) Anticuerpos específicos de polipeptido amiloide de islote humano (hiapp) y sus usos.
BRPI0809665B8 (pt) anticorpo monoclonal que se liga especificamente a endosialina
EA201291065A1 (ru) Антитела против vla-4
BR112012007082A2 (pt) anticorpos que se ligam especificamente ao receptor do fator de crescimento epidérmico